Freedman 1998.

Methods	Randomised controlled phase II study
Participants	30 ovarian cancer patients previously treated with platinum‐based chemotherapy (disease status at study entry not described)
Interventions	Subcutaneous KLH conjugate (Sialyl‐Tn) at 2 different dosages Adjuvant: Detox B
Outcomes	Survival (progression‐free interval/survival) Tumour responses Adverse events
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Information about the sequence generation process insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Allocation concealment (selection bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Reporting of attrition/exclusions insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Selective reporting (reporting bias)	Unclear risk	Information insufficient to permit judgement of ‘low risk’ or ‘high risk’; only abstract available
Other bias	High risk	Publication bias possible